A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT ID: NCT00406809

Last Updated: 2021-08-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 81 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2016-10-31

Brief Summary

The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies. The Phase 2a portion of the study is evaluating ABT-263 using a step-up dosing regimen and may be increased to the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy in subject with lymphoid malignancies. The Extension portion of the study is to allow Phase 2a subjects who remain active 1 year after the last subject enrolls or who have been on study approximately 1 year to continue receiving ABT-263 with less frequent study evaluations. Subjects in the Extension Study will continue receiving study drug for up to 7 years after the last subject transitions to the Extension Study, or until disease progression or toxicity that necessitates discontinuation (whichever comes first).

Detailed Description

Enrollment breakdown: Entered Study: Phase 1a: 39; Phase 1b: 19; Phase 2a: 33; Total: 91 Entered Treatment: Phase 1a: 38; Phase 1b: 17; Phase 2a: 26; Total: 81

Conditions

Chronic Lymphoid Leukemia; Lymphoid Malignancies; Non-Hodgkin's Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Peripheral T-cell Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1a and 1b

Relapsed or refractory lymphoid malignancies

Group Type: EXPERIMENTAL

ABT-263

Intervention Type: DRUG

Oral solution

Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.

Oral solution and tablets

Phase 2a dosing under 21 day continuous dosing.

• 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Arm A (Phase 2a)

Relapsed or refractory follicular lymphoma

Group Type: EXPERIMENTAL

ABT-263

Intervention Type: DRUG

Oral solution

Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.

Oral solution and tablets

Phase 2a dosing under 21 day continuous dosing.

• 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Arm B (Phase 2a)

Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma

Group Type: EXPERIMENTAL

ABT-263

Intervention Type: DRUG

Oral solution

Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.

Oral solution and tablets

Phase 2a dosing under 21 day continuous dosing.

• 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Extension Study

Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma

Group Type: EXPERIMENTAL

ABT-263

Intervention Type: DRUG

Oral solution

Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.

Oral solution and tablets

Phase 2a dosing under 21 day continuous dosing.

• 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Interventions

ABT-263

Oral solution

Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.

Oral solution and tablets

Phase 2a dosing under 21 day continuous dosing.

• 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnoses:

• 1a/1b - lymphoid malignancy;
• 2a, Arm A - follicular lymphoma;
• 2a, Arm B - mantle cell, peripheral or cutaneous T-cell lymphomas including mycosis fungoides and Sezary syndrome or other indolent B-cell lymphomas such as marginal zone lymphoma;
• Received at least 1 prior chemotherapy treatment regimen (P1a/1b) and relapsed or refractory disease (P2a).
• Eastern Cooperative Oncology Group (ECOG) score of <= 1.
• Magnetic Resonance Imaging (MRI)/computed tomography (CT) negative for subdural or epidural hematoma w/in 28 days prior to first dose, if clinically indicated.
• Stable dose of Selective serotonin reuptake inhibitors (SSRI) antidepressants for at least 21 days prior to 1st dose.
• Adequate bone marrow (BM) independent of any growth factor support (except with heavily infiltrated bone marrow (80% or more)):

• Absolute Neutrophil Count (ANC) >= 1000/µL;
• Platelets >= 100,000/mm3 (entry count must be independent of transfusion with in 14 days of Screening);
• Hemoglobin >= 9.0/dL.
• Adequate coagulation, renal, and hepatic function:

• Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min;
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0 x Upper Limit of Normal (ULN);
• Bilirubin <= 1.5 x ULN;
• Gilbert's Syndrome may have a bilirubin > 1.5 x ULN;
• Coagulation: Activated partial thromboplastin time (aPTT), Prothrombin Time (PT), not to exceed 1.2 x ULN
• Females must be surgically sterile, postmenopausal (at least 1 year), or negative results for a pregnancy test performed at Screening on a serum sample obtained with in 14 days prior to initial dose, and prior to dosing on a urine sample obtained on C1 D-3 (P1a) or Lead-in D1 (P1b, P2a) if > 7 days since serum results.
• Females not surgically sterile or postmenopausal (at least 1 year) and non-vasectomized males must practice birth control.
• P2a only: History of autologous stem cell transplant must be > 6 months post transplant with adequate BM independent of growth factor support per lab reference range at Screening as follows:

• Absolute Neutrophil Count (ANC) >= 1,500/µL;
• Platelets >= 125,000/mm3 (entry platelet count must be independent of transfusion with in 14 days of Screening);
• Hemoglobin >= 10.0g/dL;
• Measurable disease by International Working Group (IWG)/National Cancer Institute- sponsored Working Group (NCI-WG) criteria.
• At least one of following for Pharmacodynamics (P2a):

• archived diagnostic Formalin Fixed Paraffin Embedded (FFPE) tumor tissue with no intervening treatment since biopsy,
• core needle biopsy of malignant lymph node, or
• bone marrow aspirate or core positive for lymphoma.

• Subjects must meet the following hematology and coagulation lab criteria:

• Platelet counts must be >= 25,000/mm3 (untransfused). Platelet counts <= 50,000/mm3 must be stable and monitored at an increased frequency at the discretion of the investigator.
• Absolute Neutrophil count (ANC) >= 500/µL. ANC >= 500/µL and < 1,000/µL should be monitored at an increased frequency at the discretion of the investigator.
• Hemoglobin of >= 8.0 g/dL.
• aPTT, PT is not to exceed 1.2 x ULN.
• Chemistry values must not exceed Grade 2. Grade 2 chemistry labs should be monitored at an increased frequency at the discretion of the investigator. Subjects must meet the following chemistry criteria:

• Serum creatinine <= 3.0 x the upper normal limit (ULN) of institution's normal range. * AST and ALT <= 5.0 x the upper normal limit (ULN) of institution's normal range.
• Bilirubin <= 3.0 x ULN. Subjects with Gilbert's Syndrome may be allowed to have a Bilirubin > 3.0 x ULN based on a joint decision between the investigator and Abbott medical monitor.

Exclusion Criteria

• History of, or is, clinically suspicious for cancer-related Central Nervous System (CNS) disease, lymphoid or non-lymphoid.
• Undergone an allogeneic or autologous stem cell transplant.
• Underlying, predisposing condition of bleeding or currently exhibits signs of clinically significant bleeding.
• Recent history of non-chemotherapy induced thrombocytopenic associated bleeding with in 1 year prior to first dose.
• Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
• Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions with in 1 year prior to first dose.
• Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
• Females pregnant or breast-feeding.
• Positive for human immunodeficiency virus (HIV)
• History of other active malignancies with in the past 3 years (P1a/1b) or past 5 years (P2a), except adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent.
• Evidence of other clinically significant uncontrolled condition(s), including, but not limited to active systemic fungal infection; diagnosis of fever and neutropenia with in 1 week prior to study drug.
• Received steroid therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent.
• Received any anti-cancer therapy, including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy, with in 14 days prior to first dose of study drug, or has not recovered to <Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
• Received a biologic with in 30 days prior to first dose.
• Currently receiving or requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications that are used to maintain the patency of a central venous catheter.
• Received aspirin with in 7 days prior to first dose and during ABT-263 administration.
• Consumed grapefruit or grapefruit products with in 3 days prior to first dose.
• P1a/1b only: Diagnosed with Posttransplant lymphoproliferative disorder (PTLD); Burkitt's, Burkitt-like, or HIV-associate lymphoma; lymphoblastic lymphoma/leukemia; or multiple myeloma.
• Subject has received CYP3A inhibitors (e.g., ketoconazole, clarithromycin) within 7 days prior to the administration of the first dose of ABT-263 (P2a).
• Subject had a prior significant toxicity from another Bcl-2 family protein inhibitor (P2a).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbbVie (prior sponsor, Abbott)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mack Mabry, MD

Role: STUDY_DIRECTOR

AbbVie

Locations

Site Reference ID/Investigator# 4997

Los Angeles, California, United States

Site Reference ID/Investigator# 9104

Los Angeles, California, United States

Site Reference ID/Investigator# 2613

Bethesda, Maryland, United States

Site Reference ID/Investigator# 40243

Boston, Massachusetts, United States

Site Reference ID/Investigator# 4745

Boston, Massachusetts, United States

Site Reference ID/Investigator# 2628

Buffalo, New York, United States

Site Reference ID/Investigator# 23543

New York, New York, United States

Site Reference ID/Investigator# 2627

New York, New York, United States

Site Reference ID/Investigator# 2614

New York, New York, United States

Site Reference ID/Investigator# 5383

New York, New York, United States

Site Reference ID/Investigator# 12306

Rochester, New York, United States

Site Reference ID/Investigator# 8941

Edmonton, , Canada

Countries

United States; Canada

References

Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18.

Reference Type: BACKGROUND

PMID: 21094089 (View on PubMed)

de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021 Apr;62(4):810-818. doi: 10.1080/10428194.2020.1845332. Epub 2020 Nov 25.

Reference Type: DERIVED

PMID: 33236943 (View on PubMed)

Other Identifiers

M06-814

Identifier Type: -

Identifier Source: org_study_id

NCT00408811

Identifier Type: -

Identifier Source: nct_alias